Enanta Pharmaceuticals
Utility Patents
Last updated:
List of all Enanta Pharmaceuticals patents 64 in total
| Status | Patent |
|---|---|
Grant | Utility: Heterocyclic compounds as anti-viral agents Filling date: 6 Sep 2025 Issue date: 23 Aug 2022 |
Grant | Utility: Benzodiazepine derivatives as RSV inhibitors Filling date: 6 Sep 2025 Issue date: 19 Jul 2022 |
Grant | Utility: Spiropyrrolidine derived antiviral agents Filling date: 6 Sep 2025 Issue date: 12 Jul 2022 |
Grant | Utility: Functionalized heterocycles as antiviral agents Filling date: 6 Sep 2025 Issue date: 5 Jul 2022 |
Grant | Utility: Functionalized peptides as antiviral agents Filling date: 6 Sep 2025 Issue date: 14 Jun 2022 |
Grant | Utility: Spiropyrrolidine derived antiviral agents Filling date: 6 Sep 2025 Issue date: 7 Jun 2022 |
Grant | Utility: Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof Filling date: 6 Sep 2025 Issue date: 31 May 2022 |
Grant | Utility: Spiropyrrolidine derived antiviral agents Filling date: 6 Sep 2025 Issue date: 24 May 2022 |
Grant | Utility: Spiropyrrolidine derived antiviral agents Filling date: 6 Sep 2025 Issue date: 10 May 2022 |
Grant | Utility: Macrocyclic spiropyrrolidine derived antiviral agents Filling date: 6 Sep 2025 Issue date: 3 May 2022 |
Grant | Utility: Benzodiazepine derivatives as RSV inhibitors Filling date: 6 Sep 2025 Issue date: 22 Feb 2022 |
Grant | Utility: Functionalized heterocycles as antiviral agents Filling date: 6 Sep 2025 Issue date: 1 Feb 2022 |
Grant | Utility: Hepatitis B antiviral agents Filling date: 6 Sep 2025 Issue date: 1 Feb 2022 |
Grant | Utility: Functionalized heterocycles as antiviral agents Filling date: 6 Sep 2025 Issue date: 14 Dec 2021 |
Grant | Utility: Heterocyclic compounds as RSV inhibitors Filling date: 6 Sep 2025 Issue date: 23 Nov 2021 |
Grant | Utility: Heterocyclic compounds as RSV inhibitors Filling date: 6 Sep 2025 Issue date: 17 Aug 2021 |
Grant | Utility: Substituted heterocycles as antiviral agents Filling date: 6 Sep 2025 Issue date: 13 Jul 2021 |
Grant | Utility: Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof Filling date: 6 Sep 2025 Issue date: 22 Jun 2021 |
Grant | Utility: Isoxazole analogs as FXR agonists and methods of use thereof Filling date: 6 Sep 2025 Issue date: 15 Jun 2021 |
Grant | Utility: Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof Filling date: 6 Sep 2025 Issue date: 18 May 2021 |
Grant | Utility: Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof Filling date: 6 Sep 2025 Issue date: 27 Apr 2021 |
Grant | Utility: Heterocyclic compounds as RSV inhibitors Filling date: 6 Sep 2025 Issue date: 13 Apr 2021 |
Grant | Utility: Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof Filling date: 6 Sep 2025 Issue date: 6 Apr 2021 |
Grant | Utility: Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof Filling date: 6 Sep 2025 Issue date: 6 Apr 2021 |
Grant | Utility: Process for preparation of sulfonyl carbamate bile acid derivatives Filling date: 6 Sep 2025 Issue date: 30 Mar 2021 |
Grant | Utility: Hepatitis B antiviral agents Filling date: 6 Sep 2025 Issue date: 23 Mar 2021 |
Grant | Utility: Process for preparation of sulfonylurea bile acid derivatives Filling date: 6 Sep 2025 Issue date: 16 Mar 2021 |
Grant | Utility: Hepatitis B antiviral agents Filling date: 6 Sep 2025 Issue date: 2 Mar 2021 |
Grant | Utility: Processes for the preparation of benzodiazepine derivatives Filling date: 6 Sep 2025 Issue date: 2 Feb 2021 |
Grant | Utility: Combination pharmaceutical agents as RSV inhibitors Filling date: 6 Sep 2025 Issue date: 5 Jan 2021 |
Grant | Utility: Benzodiazepine derivatives as RSV inhibitors Filling date: 6 Sep 2025 Issue date: 15 Dec 2020 |
Grant | Utility: Functionalized heterocycles as antiviral agents Filling date: 6 Sep 2025 Issue date: 15 Dec 2020 |
Grant | Utility: Processes for the resolution of benzodiazepin-2-one and benzoazepin-2-one derivatives Filling date: 6 Sep 2025 Issue date: 1 Dec 2020 |
Grant | Utility: Heterocyclic compounds as RSV inhibitors Filling date: 6 Sep 2025 Issue date: 1 Dec 2020 |
Grant | Utility: Isoxazole derivatives as FXR agonists and methods of use thereof Filling date: 6 Sep 2025 Issue date: 10 Nov 2020 |
Grant | Utility: Heterocyclic compounds as RSV inhibitors Filling date: 6 Sep 2025 Issue date: 1 Sep 2020 |
Grant | Utility: Benzimidazole derivatives Filling date: 6 Sep 2025 Issue date: 25 Aug 2020 |
Grant | Utility: Aryldiazepine derivatives as RSV inhibitors Filling date: 6 Sep 2025 Issue date: 25 Aug 2020 |
Grant | Utility: Hepatitis B antiviral agents Filling date: 6 Sep 2025 Issue date: 11 Aug 2020 |
Grant | Utility: Hepatitis B antiviral agents Filling date: 6 Sep 2025 Issue date: 4 Aug 2020 |
Grant | Utility: Hepatitis B antiviral agents Filling date: 6 Sep 2025 Issue date: 28 Jul 2020 |
Grant | Utility: Hepatitis B antiviral agents Filling date: 6 Sep 2025 Issue date: 7 Jul 2020 |
Grant | Utility: Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof Filling date: 6 Sep 2025 Issue date: 30 Jun 2020 |
Grant | Utility: Isoxazole analogs as FXR agonists and methods of use thereof Filling date: 6 Sep 2025 Issue date: 23 Jun 2020 |
Grant | Utility: Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof Filling date: 6 Sep 2025 Issue date: 16 Jun 2020 |
Grant | Utility: Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof Filling date: 6 Sep 2025 Issue date: 16 Jun 2020 |
Grant | Utility: Process for preparation of sulfonyl carbamate bile acid derivatives Filling date: 6 Sep 2025 Issue date: 9 Jun 2020 |
Grant | Utility: Azepin-2-one derivatives as RSV inhibitors Filling date: 6 Sep 2025 Issue date: 12 May 2020 |
Grant | Utility: Hepatitis B antiviral agents Filling date: 6 Sep 2025 Issue date: 5 May 2020 |
Grant | Utility: Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof Filling date: 6 Sep 2025 Issue date: 24 Mar 2020 |
Showing 1 to 50 of 64 patents.